In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations/FDA form 483 warnings topped the list, capturing 32 percent of respondents’ votes.
In Q2 2019, ISR asked 101 respondents who outsource oral dose drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations/FDA form 483 warnings topped the list, capturing 30 percent of respondents’ votes.
In Q2 2019, ISR asked 101 respondents who outsource sterile injectable drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations/FDA form 483 warnings topped the list, capturing 25 percent of respondents’ votes.
If you're using one of these six excuses for ignoring pharma market research, you're failing to understand barriers to success, missing the market’s perspective, and leaving assumptions unvalidated.
This website uses cookies to ensure you get the best experience on our website. Learn more
